tbuckley/cabot-search huggingface dataset:
P761Antibody mediated rejection related with CMV and EBV infection in heart transplants recipients: a possible relation with infection and complement activation.
Authors: M Fedrigo, D Abate, D Sgarabotto, G Feltrin, C Castellani, A Gambino, G Gerosa, M Valente, G Thiene, A Angelini
Journal: Cardiovascular Research (2014)

Aim: Aim of the present study was to investigate the relationship between CMV and EBV infection and the occurrence of antibody mediated rejection (AMR) in a cohort of adult heart transplant recipients (HTXs). Materials and Methods: 47 adult HTX patients were enrolled in a case-control study from June 2010 to June 2012, 24 of them with humoral rejection and 23 without. Endomyocardial biopsies (EMBs) were routinely performed and pathological diagnosis of AMR assessed according to ISHLT 2011. Donor specific antibodies titles were evaluated at the same time of EMBs biopsy. Routine surveillance for viral reactivation or infection comprised weekly determination of whole blood CMV DNAemia during the first 100 days post-transplant. CMV and EBV DNAemia was evaluated using real-time PCR. We divided the cohort study in two groups according to time since HTx as early (1-90 days) and late (91-360 days). Results: In the AMR group the EBV infection was present in 13 cases (13/24, 54%) and CMV in 10 cases (10/24, 42%). In the control group the cases of pts with EBV were 2/23 (9%), while CMV were 4/23 (17%). In the early period EBV infection was present in 12/24 cases (50%, p=0.000) and CMV infection was present in 10/23 cases (p=0.042). In the late period EBV was present in 6/24 cases (25%, p=0.002) and CMV in 1/23 (4%, p=0.000). Conclusions: EBV and CMV infections during follow-up post heart transplantation occurred more frequently in patients with AMR suggesting that virus could act as a trigger in humoral rejection.
Abstract 3342: Specific inhibition of IKKβ induces caspase-independent cell death in the ovarian cancer stem cells
Authors: Ayesha B. Alvero, Michele K. Montagna, Jennie Holmberg, Gil Mor
Journal: Cancer Research (2010)

Abstract Introduction: Current studies show that the cancer stem cells represent the chemo-resistant phenotype and therefore may survive chemotherapy to eventually rebuild the tumor. Our group previously identified and characterized the ovarian cancer stem cells using CD44 and MyD88 as a marker and showed that these cells have a constitutively active IKKβ/NFκB axis. We hypothesize that specific targeting of this pathway may affect survival of the ovarian cancer stem cells. Methods: A panel of CD44+/MyD88+ ovarian cancer stem cells were treated with increasing concentrations of the specific IKKβ inhibitor, BAY 11-7082 (0.1, 0.5 1, 5, and 10 μg/ml). Effect on cell growth was monitored using the Incucyte real time imaging system and cell viability was determined using the Celltiter 96 assay. Specific inhibition of IKKβ was determined by: (a) the effect on the mTOR pathway by analyzing levels of phospho-S6 kinase and (b) by determining the effect on TNFα-induced NFκB activity by measuring levels of IκB. Activity of caspases- 3/7, −8, and −9 was measured using Caspase-Glo assay and levels of XIAP monitored using western blot analysis. Effect on mitochondrial membrane potential was measured using flow cytometry after staining with JC1 dye. In vivo activity was monitored using a s.c. ovarian cancer xenograft model in nude mice. The effect of BAY 11-7082 (10 mg/kg every other day given i.p.) was compared to carboplatin (40mg/kg q7d given i.p.) and paclitaxel (10mg/kg q3d given i.p.). Results: Treatment with BAY 11-7082 inhibited cell growth and decreased cell viability in all ovarian cancer stem cell cultures tested in a dose and time dependent manner with GI50 at ∼ 5μg/ml. Specific inhibition of IKKβ was observed at this dose by a decrease in phospho-p70S6 kinase and inhibition of TNFα-induced IκB degradation. Cell death was caspase-independent with no significant increase in caspases 3/7, 8, nor 9 and no effect on the levels of XIAP. Cell death was associated with loss of mitochondrial membrane potential with more than 90% of cells showing a shift in JC1 fluorescence from red to green in 4h. In vivo studies showed that BAY 11-7082 is able to inhibit tumor growth with T/C of 64%, significantly better than carboplatin and paclitaxel (T/C 87% and 74%, p=0.009 and 0.0025, respectively). Conclusion: The capacity of the cancer stem cells to survive chemotherapy and rebuild the tumor represent a major target to inhibit recurrence in ovarian cancer patients. The demonstration that specific targeting of IKKβ can induce cell death in the ovarian cancer stem cells opens new therapeutic options for ovarian cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3342.
Abstract 1594: Sustained release of drug eluting nanoparticles from implantable devices for loco-regional chemoradiation therapy.
Authors: Rajiv Kumar, Jodi Belz, Stacey Markovic, Tej Jadhav, Paul Nguyen, Mark Niedre, Anthony DAmico, Mike Makrigiorgos, Robert Cormack, Srinivas Sridhar
Journal: Cancer Research (2013)

Abstract Systemic chemotherapy is often used with radiation therapy in the management of prostate, cervix and lung cancer patients, but leads to severe systemic toxicities. We have introduced a new modality of loco-regional chemoradiation therapy termed in-situ image guided radiation therapy (BIS-IGRT) that offers the potential to deliver planned, localized and sustained delivery of chemotherapy agent, without systemic toxicities, as part of routine minimally invasive image guided radiation therapy procedures. Such image guided chemoradiation therapy requires characterization of the drug distribution produced by implantable drug eluters. This work presents imaging based means to measure temporal and spatial properties of diffusion distributions around spacers coated with dye-loaded nanoparticles. The distribution of 250nm silica nanoparticles (NP) conjugated to Cyanine 7.5 dye was evaluated with a custom built high-speed near-infrared small animal imaging platform providing 0.1 millimeter spatial resolution with &amp;gt;1Hz image acquisition rate. A brachytherapy spacer loaded with the Cy7.5/silica NP was injected subcutaneously on the left hind flank of a mouse and one was inserted into a xenograft tumor on the opposite flank as part of an approved animal research protocol. The mouse was imaged more than 36 days. The in vivo imaging experiments show that the area of high signal increases with time suggesting that NP accumulate in the vicinity of a spacer without diffusing to the rest of the body. The spatial and temporal characteristics of NP accumulation indicate that a BIS-IGRT approach may provide an effective means to improve the therapeutic ratio of brachytherapy. Conclusion: In-vivo measurements demonstrate that NP remain resident in the vicinity of the implanted eluting spacers with accumulation over times appropriate to improve brachytherapy's therapeutic ratio. Future work will optimize the NP and substrate properties of an implantable spacer to attain the optimal chemotherapy distributions for simultaneous placement during image guided brachytherapy implants. We acknowledge partial support from NSF DGE 0965843 and HHS/5U54CA151881-02. Citation Format: Rajiv Kumar, Jodi Belz, Stacey Markovic, Tej Jadhav, Paul Nguyen, Mark Niedre, Anthony DAmico, Mike Makrigiorgos, Robert Cormack, Srinivas Sridhar. Sustained release of drug eluting nanoparticles from implantable devices for loco-regional chemoradiation therapy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1594. doi:10.1158/1538-7445.AM2013-1594
Abstract 4923: Identification of invasive and metastatic potential of Tpl2 knockout keratinocytes.
Authors: Katie L. Decicco-Skinner, Sarah Jung, Tracy Tabib, Curtis Gwilliam, Hepzi Alexander, Sarah Goodheart, Adam Morin, Alex Cvitan, Jonathan Wiest
Journal: Cancer Research (2013)

Abstract Skin cancer is the most common form of cancer in the United States, with an estimated two million cases diagnosed annually. Tpl2 (MAP3K8) is a serine threonine protein kinase in the mitogen-activated protein kinase (MAPK) signal transduction cascade. Tpl2 was identified by our laboratory as having a tumor suppressive function in skin carcinogenesis. Tpl-2 knockout mice develop significantly more tumors than matched wildtype controls and have a larger degree of inflammation when challenged with 12-O-tetradecanoylphorbol-13-acetate (TPA). However, it is unknown whether the tumors that develop in Tpl2 knockout mice are more aggressive and invasive than skin tumors in wildtype mice. Therefore, we compared the invasive and metastatic potential of keratinocytes from wildtype and Tpl2 knockout mice. Using various techniques including gene microarray, real-time polymerase chain reaction, and zymography we found MMP-2 and MMP-9 matrix metalloproteinases to be significantly up-regulated in Tpl-2−/- keratinocytes. Additionally, Tpl-2−/- keratinocytes have altered migration rates, significantly higher malignant conversion rates and increased angiogenesis when compared to wildtype keratinocytes. Moreover, protein arrays identified several angiogenic factors, in addition to the MMP's, induced in Tpl-2−/- keratinocytes. In summary, our studies demonstrate skin tumors from Tpl-2−/- mice have the potential to be more aggressive, invasive, and metastatic than tumors in control animals. Citation Format: Katie L. Decicco-Skinner, Sarah Jung, Tracy Tabib, Curtis Gwilliam, Hepzi Alexander, Sarah Goodheart, Adam Morin, Alex Cvitan, Jonathan Wiest. Identification of invasive and metastatic potential of Tpl2 knockout keratinocytes. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4923. doi:10.1158/1538-7445.AM2013-4923
Women's Aspirin, Beta-Carotene Study on Hold
Authors: K. Smigel
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Women's Aspirin, Beta-Carotene Study on Hold Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 10, 15 May 1991, Page 681, https://doi.org/10.1093/jnci/83.10.681-a Published: 15 May 1991
758 ENTECAVIR PLUS PEGINTERFERON alfa-2a vs. ENTECAVIR ALONE IN THE TREATMENT OF HEPATITIS B e ANTIGEN-POSITIVE CHRONIC HEPATITIS B: AN INTERIM REPORT
Authors: C.-J. Liu, C.-C. Wang, S.-S. Yang, C.-W. Su, L.-Y. Liao, T.-H. Lee, W.-L. Chuang, C.-L. Chen, R.-N. Chien, C.-Y. Peng, C.-M. Lee, Y.-F. Lee, J.-H. Kao, P.-J. Chen, D.-S. Chen
Journal: Journal of Hepatology (2013)
AB0384 Prevalence of irreversible articular damage and orthopedic surgeries in hispanics with rheumatoid arthritis in the united states (US):
Authors: R. Moran, S. Dolatabadi, G.A. Karpouzas
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Structural damage has been associated with poor functional outcomes and disability in Rheumatoid Arthritis (RA). Hispanics with RA in the US display worse functional outcomes, despite similar disease control to Caucasians. However, the presence of structural articular damage and orthopedic surgeries performed in this subset remains unknown. <h3>Objectives</h3> To explore the prevalence of irreversible articular damage, orthopedic surgeries, joint replacements and their distribution in US Hispanics with RA. <h3>Methods</h3> Two hundred and ninety five subjects from a single center were evaluated. Demographics, serologies, radiographs, and treatments were recorded. Irreversible articular damage (IAD) was defined as presence of subluxation, arthrodesis, fusion, or prosthesis). Orthopedic surgeries in upper and lower extremities as well as joint replacement surgeries (JRS) were captured. Non-parametric Mann-Whitney U and Fisher’s exact tests compared continuous and categorical variables respectively. <h3>Results</h3> Patients are predominantly females with robustly seropositive, chronic, and well controlled RA. IAD was present in 35% of patients and was significantly higher on subjects treated with biologics (43% vs. 26%, p=0.002- table 1). Similarly, the majority of patients with IAD received biologics (65% vs. 39%, p=0.002). Orthopedic surgeries occurred in 39/295 (13%) of patients, or 39/102 (38%) of those with IAD. A higher proportion of subjects on biologics underwent surgery (19% vs. 8% on DMARDs, p=0.006). Concordantly, surgeries occurred predominantly in patients on biologics (69% vs. 31%, p=0.02). Most patients undergoing surgery, had 2 or more procedures (72% vs. 28%, p=0.0002). Overall, 39 subjects underwent 88 procedures; 66/88 (76%) occurred on the lower extremities, and 16/88 (18%) on the upper extremities. The majority were joint replacements (65/88 or 75%), most occurred on the lower extremities (89% vs. 11%), and tended to be more common in subjects on biologics. <h3>Conclusions</h3> One third of US Hispanics experience irreversible articular damage, especially those treated with biologics, suggesting more severe disease in that subset. Orthopedic surgeries occur commonly, most are joint replacements, are more frequent in subjects receiving biologics, and predominantly happen in the lower extremities. <h3>Disclosure of Interest</h3> None Declared
OP0267-PARE Creating a Successful Support System for Patient Involvement in Arthritis Research in the UK Both Locally and Nationally
Authors: C. A. Rhodes
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Keele University ARUK Primary Care Centre has set up a successful recruitment and support system for patient involvement in research. There are now 50 plus patients, involved in over 35 projects investigating all aspects of life with a musculoskeletal condition. The projects use both quantitative and qualitative methods such as cohort studies, randomised control trials and observations and interviews, exploring patients’ experience of living with musculoskeletal conditions and their treatments. <h3>Objectives</h3> We will describe examples of involvement in projects including: A clinical trial to test out a model consultation for OA (Osteoarthritis) delivered by a GP (General Practitioner) and nurse;the piloting of an international OA Trial Bank; and a patient led research project on public priorities for research in joint pain. By describing these studies we aim to highlight how patients have been involved in the different stages of the research cycle including: - Identifying and prioritising research - Designing and managing research projects - Disseminating findings We will describe the support systems that underpin involvement, for example, a set of guides produced to assist patients who work with researchers at the Centre and the appointment of dedicated staff in paid support roles. We will also highlight the importance of our group’s links to the national organisation INVOLVE, that was set up to support greater involvement in public health and social care research <h3>Conclusions</h3> Our open model of recruitment attracting “expertise by experience” has succeeded and is underpinned by an effective system including the development of PPI (Patient and Public Involvement) support roles within our Centre: - A PPI Coordinator who matches the patient expertise of their condition to relevant projects and keeps an overview of the whole process - A User Support Worker who offers consistent guidance and accompanies patients to project meetings This has made sure that PPI is embedded appropriately within our portfolio of research projects <h3>Disclosure of Interest</h3> None Declared
Lutein Cyst Inadvertently Detected on Tc-99m MDP Whole-Body Bone Scintigraphy
Authors: TOSHIYUKI KIDA, SHIGEO TAKAHASHI
Journal: Clinical Nuclear Medicine (1998)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious IssuesPublished Online First Collections ACNM MeetingsCMECommunication in OrganizationCOVID-19Feedback and RewardsFrom the American College of Nuclear MedicineHighly Cited and Frequently Read ArticlesPlanning and Conducting Meetings EffectivelyQuality and Safety in Health CareRecruitment of New PhysiciansTips for Giving a Memorable PresentationTips for LeadersTips for Physicians in Getting the Right Job ACNM ArticlesACNM Website For Authors Submit a ManuscriptInformation for AuthorsLanguage Editing ServicesAuthor PermissionsLippincott&#174; Preprints Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
The Illusion of Certainty
Authors: Arthur P. Wolinsky
Journal: New England Journal of Medicine (1996)

A 42-year-old man saw a physician because he had had pain in both hips for several months. The pain was made worse by climbing stairs and ladders and was more severe on the left side. Ibuprofen provided no relief. He thought the problem might be bursitis; several months earlier he had had bursitis in his shoulder that had felt similar and was relieved by an injection of cortisone.Physical examination revealed very strong femoral and pedal pulses and no vascular bruits. The range of motion of both hips was normal, and extending and flexing the hips caused minimal . . .
Detection of Bilateral Multifocal Breast Cancer Using Tc-99m Sestamibi Imaging
Authors: E Derebek, P Balci, H Alanyali, M A Kocdor, G Capa, I B Gorken, B Degirmenci, M Alakavuklar, T Canda, H Durak
Journal: Clinical Nuclear Medicine (1999)

Early determination that breast cancer is bilateral and multifocal can change therapy strategy and, subsequently, mortality and morbidity rates. The authors present a case with bilateral, multifocal breast cancer detected only by Tc-99m sestamibi imaging.Early and delayed Tc-99m sestamibi imaging and dynamic MRI were performed in a patient with a right-sided lesion shown on mammography.Although early Tc-99m sestamibi imaging detected bilateral breast cancer foci, both dynamic MRI and mammography missed the lesion in the left breast. Additional lesions seen on delayed Tc-99m sestamibi images of the left breast, which were initially thought to be benign, completely disappeared after concomitant chemotherapy and radiotherapy, suggesting multifocal malignant lesions in the left breast.This case suggests that Tc-99m sestamibi may be useful for detecting bilateral cancer, and delayed imaging may give additional information regarding the possible multifocal nature of the disease.
AB0447 Comparison of efficacy of four biological agents for rheumatoid arthritis patients using the HRQOL questionnaire and depression scale:
Authors: Y. Miwa, H. Furuya, R. Yanai, K. Ohtsuka, M. Sato, R. Takahashi, K. Wakabayashi, N. Yajima, T. Kasama, M. Hosaka
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Health-related quality of life (HRQoL) as a patient-reported outcome in rheumatoid arthritis (RA) has become an important tool in the clinical evaluation of patient preferences and perceptions of individual health. <h3>Objectives</h3> The objective of this study was to compare the validity of the HRQoL with respect to depression in RA patients treated with infliximab, etanercept, adalimumab or tocilizumab. <h3>Methods</h3> One hundred seven RA patients (infliximab, 47 pts; etanercept, 17 pts; adalimumab, 25 pts; tocilizumab, 18 ptts) were assessed prior to treatment and again at 30 weeks after initiation of therapy. The age, gender, and steroid dosage were obtained for each participant, and the HRQoL questionnaire (modified health assessment questionnaire (mHAQ) and Short Form (SF)-36) and depression scale (Japanese version of the structured interview guide for the Hamilton Depression rating scale (HAM-D) and the Self-rating Depression Scale (SDS)) were administered to patients. The primary endpoint was the assessment of clinical improvements, and the secondary endpoints were assessments of the changes in the HRQoL and depression scale. <h3>Results</h3> After 30 weeks of treatment, the DAS28 score of patients treated with tocilizumab was lower than the score of patients treated with adalimumab (p&lt;0.05). There were no significant differences in the percentage of low disease activity and remission. Although no significant differences were found for the HAM-D and SDS scores, the changes in the scores of the mHAQ—role physical, body pain, vitality, social function, role emotion and mental health—as measured by the SF-36 differed significantly between the four groups. Specifically, etanercept treatment was associated with significant improvement as measured by HRQoL compared with adalimumab and tocilizumab therapy. However, there were no significant differences with respect to age, gender, steroid dosage, DAS28 (before treatment) and physical function and general health as measured by the SF-36. <h3>Conclusions</h3> In this study, etanercept treatment was associated with a significant improvement in many items of the HRQoL evaluation compared with other drugs, without taking into account the efficacy of drug. Although mental health as measured by the SF-36 was improved, the HAM-D and SDS scores did not differ between the four groups. <h3>Disclosure of Interest</h3> Y. Miwa Grant/Research support from: tanabemitsubishi, wyeth, abott, eizai, chugai, bristol, H. Furuya: None Declared, R. Yanai: None Declared, K. Ohtsuka: None Declared, M. Sato: None Declared, R. Takahashi: None Declared, K. Wakabayashi: None Declared, N. Yajima: None Declared, T. Kasama: None Declared, M. Hosaka: None Declared